Li H, Qin Z, Huang X, Wei Z, Deng J
Heliyon. 2025; 11(4):e42720.
PMID: 40066042
PMC: 11891687.
DOI: 10.1016/j.heliyon.2025.e42720.
Cui J, An Z, Zhou X, Zhang X, Xu Y, Lu Y
BMC Cancer. 2024; 24(1):1128.
PMID: 39256698
PMC: 11389553.
DOI: 10.1186/s12885-024-12863-w.
Jalaeian H, Richardson K, Kozlowski K, Patel A, Venkat S
J Thorac Dis. 2024; 16(7):4310-4318.
PMID: 39144294
PMC: 11320254.
DOI: 10.21037/jtd-24-240.
Hasani A
Microrna. 2024; 13(3):167-174.
PMID: 38963099
DOI: 10.2174/0122115366296148240530072346.
Madama D, Carrageta D, Guerra-Carvalho B, Botelho M, Oliveira P, Cordeiro C
Metabolites. 2023; 13(12).
PMID: 38132862
PMC: 10744969.
DOI: 10.3390/metabo13121180.
Investigating the role of let-7a microRNA in cisplatin sensitivity of A549 lung cancer cells.
Aslan E, Aydin E
Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(6):3979-3984.
PMID: 37991541
DOI: 10.1007/s00210-023-02858-y.
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors.
Huang C, Lin C, Su T, Yang C, Tsai T, Hsu C
BMC Cancer. 2023; 23(1):234.
PMID: 36915101
PMC: 10010021.
DOI: 10.1186/s12885-023-10698-5.
In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation.
Chen J, Zhai J, Li M, Liu S, Gong X, Yu H
Cancer Cell Int. 2023; 23(1):21.
PMID: 36759818
PMC: 9909954.
DOI: 10.1186/s12935-022-02723-7.
Genistein-induced mitochondrial dysfunction and FOXO3a/PUMA expression in non-small lung cancer cells.
Chan L, Pang Y, Wang Y, Zhu D, Taledaohan A, Jia Y
Pharm Biol. 2022; 60(1):1876-1883.
PMID: 36200643
PMC: 9553144.
DOI: 10.1080/13880209.2022.2123933.
Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients.
Li W, Bi Z, Wu J, Duan X, Pang L, Jing Y
Front Oncol. 2022; 12:772102.
PMID: 35957880
PMC: 9359314.
DOI: 10.3389/fonc.2022.772102.
Theabrownins Produced via Chemical Oxidation of Tea Polyphenols Inhibit Human Lung Cancer Cells and by Suppressing the PI3K/AKT/mTOR Pathway Activation and Promoting Autophagy.
Wang Y, Yuan Y, Wang C, Wang B, Zou W, Zhang N
Front Nutr. 2022; 9:858261.
PMID: 35529455
PMC: 9070389.
DOI: 10.3389/fnut.2022.858261.
Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFR and EGFR.
Aboelez M, Belal A, Xiang G, Ma X
J Enzyme Inhib Med Chem. 2022; 37(1):1196-1211.
PMID: 35470756
PMC: 9067978.
DOI: 10.1080/14756366.2022.2062338.
Negative correlations of psychological distress with quality of life and immunotherapy efficacy in patients with advanced NSCLC.
Bi Z, Li W, Zhao J, Pang L, Jing Y, Zhang X
Am J Cancer Res. 2022; 12(2):805-815.
PMID: 35261803
PMC: 8899984.
Systemic immune microenvironment and regulatory network analysis in patients with lung adenocarcinoma.
Liu L, Xu S, Huang L, He J, Liu G, Ma S
Transl Cancer Res. 2022; 10(6):2859-2872.
PMID: 35116596
PMC: 8797838.
DOI: 10.21037/tcr-20-2275.
The tumour suppressor CCDC6 is involved in ROS tolerance and neoplastic transformation by evading ferroptosis.
Morra F, Merolla F, Marino F, Catalano R, Franco R, Chieffi P
Heliyon. 2021; 7(11):e08399.
PMID: 34841108
PMC: 8605351.
DOI: 10.1016/j.heliyon.2021.e08399.
Identification of the molecular function of tripartite motif containing 58 in human lung cancer.
Shi Y
Oncol Lett. 2021; 22(3):685.
PMID: 34434284
PMC: 8335731.
DOI: 10.3892/ol.2021.12946.
Altered miR-93-5p/miR-18a expression in serum for diagnosing non-small cell lung cancer.
Shao L, Lu X, Zhou Y, Wang Y, Wang X, Zhuang Z
Am J Transl Res. 2021; 13(5):5073-5079.
PMID: 34150094
PMC: 8205697.
Use of cucurbitacins for lung cancer research and therapy.
Liu M, Yan Q, Peng B, Cai Y, Zeng S, Xu Z
Cancer Chemother Pharmacol. 2021; 88(1):1-14.
PMID: 33825035
DOI: 10.1007/s00280-021-04265-7.
Heterodimeric IL-15 in Cancer Immunotherapy.
Bergamaschi C, Stravokefalou V, Stellas D, Karaliota S, Felber B, Pavlakis G
Cancers (Basel). 2021; 13(4).
PMID: 33671252
PMC: 7922495.
DOI: 10.3390/cancers13040837.
Toll-Like Receptor 7 Mediates Inflammation Resolution and Inhibition of Angiogenesis in Non-Small Cell Lung Cancer.
Liotti F, Marotta M, Sorriento D, Pone E, Morra F, Melillo R
Cancers (Basel). 2021; 13(4).
PMID: 33578955
PMC: 7916730.
DOI: 10.3390/cancers13040740.